Annals of Oncology Advance Access published online on February 7, 2007
Annals of Oncology, doi:10.1093/annonc/mdl498
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Estimates of the cancer incidence and mortality in Europe in 2006
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
* Correspondence to: Prof P. Boyle, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Tel +33-4-72-73-84 85; Fax: +33-4-72-86-50. E-mail: director{at}iarc.fr
Background: Monitoring the evolution of the cancer burden in Europe is of great value. Estimates of the cancer burden in Europe have been published for 2004 and estimates are now being presented for cancer incidence and mortality in Europe for 2006.
Methods: The most recent sources of cancer incidence and mortality data have been collected and projections have been carried out using short-term prediction methods to produce estimated rates for 2006. Additional estimation was required where national incidence data were not available, and the method involved the projection of the aggregations of cancer incidence and mortality data from representative cancer registries. The estimated 2006 rates were applied to the corresponding estimated country population to obtain the best estimates of the cancer incidence and mortality in Europe in 2006.
Results: In 2006 in Europe, there were an estimated 3 191 600 cancer cases diagnosed (excluding nonmelanoma skin cancers) and 1 703 000 deaths from cancer. The most common form of cancers was breast cancer (429 900 cases, 13.5% of all cancer cases), followed by colorectal cancers (412 900, 12.9%) and lung cancer (386 300, 12.1%). Lung cancer, with an estimated 334 800 deaths (19.7% of total), was the most common cause of death from cancer, followed by colorectal (207 400 deaths), breast (131 900) and stomach (118 200) cancers.
Conclusions: The total number of new cases of cancer in Europe appears to have increased by 300 000 since 2004. With an estimated 3.2 million new cases (53% occurring in men, 47% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. Evidence-based public health measures exist to reduce the mortality of breast and colorectal cancer while the incidence of lung cancer, and several other forms of cancer, could be diminished by improved tobacco control.
cancer, deaths, Europe, incidence, mortality, predictions
Received for publication December 14, 2006. Accepted for publication December 18, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kozu, G. Iinuma, Y. Ohashi, Y. Saito, T. Akasu, D. Saito, D. B. Alexander, M. Iigo, T. Kakizoe, and H. Tsuda Effect of Orally Administered Bovine Lactoferrin on the Growth of Adenomatous Colorectal Polyps in a Randomized, Placebo-Controlled Clinical Trial Cancer Prevention Research, November 1, 2009; 2(11): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Sun, M. Hang, W. Xu, W. Mao, X. Hang, M. Li, and J. Zhang Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer Jpn. J. Clin. Oncol., October 1, 2009; (2009) hyp116v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. CSEJTEI, A. TIBOLD, K. KOLTAI, Z. VARGA, I. SZANYI, G. GOBEL, I. PRANTNER, D. STEFFLER, G. FEHER, A. DE BLASIO, et al. Association between XRCC1 Polymorphisms and Head and Neck Cancer in a Hungarian Population Anticancer Res, October 1, 2009; 29(10): 4169 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hassan, M. G. M. Hunink, A. Laghi, P. J. Pickhardt, A. Zullo, D. H. Kim, F. Iafrate, and E. Di Giulio Value-of-Information Analysis to Guide Future Research in Colorectal Cancer Screening Radiology, September 29, 2009; (2009) radiol.2533090234v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Duffy, C. Sturgeon, R. Lamerz, C. Haglund, V. L. Holubec, R. Klapdor, A. Nicolini, O. Topolcan, and V. Heinemann Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report Ann. Onc., September 8, 2009; (2009) mdp332v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rchaidia, B. Dierckx de Casterle, L. De Blaeser, and C. Gastmans Cancer Patients' Perceptions of the Good Nurse: a Literature Review Nursing Ethics, September 1, 2009; 16(5): 528 - 542. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L Kasperzyk, K. Fall, L. A Mucci, N. Hakansson, A. Wolk, J.-E. Johansson, S.-O. Andersson, and O. Andren One-carbon metabolism-related nutrients and prostate cancer survival Am. J. Clinical Nutrition, September 1, 2009; 90(3): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Meloni, A. Andreano, P. F. Laeseke, T. Livraghi, S. Sironi, and F. T. Lee Jr Breast Cancer Liver Metastases: US-guided Percutaneous Radiofrequency Ablation--Intermediate and Long-term Survival Rates Radiology, August 25, 2009; (2009) radiol.2533081968v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Kenne Sarenmalm, A.-L. Thoren-Jonsson, F. Gaston-Johansson, and J. Ohlen Making Sense of Living Under the Shadow of Death: Adjusting to a Recurrent Breast Cancer Illness Qual Health Res, August 1, 2009; 19(8): 1116 - 1130. [Abstract] [PDF]
|
|
|
|
|
|
S. FRESE, A. SCHULLER, M. FRESE-SCHAPER, M. GUGGER, and R. A. SCHMID Cytotoxic Effects of Camptothecin and Cisplatin Combined with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2L/TRAIL) in a Model of Primary Culture of Non-small Cell Lung Cancer Anticancer Res, August 1, 2009; 29(8): 2905 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Leow, J. Chesebrough, K. T. Coffman, C. A. Fazenbaker, J. Gooya, D. Weng, S. Coats, D. Jackson, B. Jallal, and Y. Chang Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib Mol. Cancer Ther., August 1, 2009; 8(8): 2131 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Hahn, R. T. Zon, M. Yu, F. O. Ademuyiwa, T. Jones, W. Dugan, C. Whalen, R. Shanmugam, T. Skaar, and C. J. Sweeney A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67 Ann. Onc., July 15, 2009; (2009) mdp244v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Auvinen, J. Raitanen, S. Moss, H. J. de Koning, J. Hugosson, T. Tammela, M. Roobol, H. Lilja, and M. Hakama Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2000 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Ghosal, P Kloer, and K E Lewis A review of novel biological tools used in screening for the early detection of lung cancer Postgrad. Med. J., July 1, 2009; 85(1005): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Guarneri and P. Conte Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy Oncologist, July 1, 2009; 14(7): 645 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Regge, C. Laudi, G. Galatola, P. Della Monica, L. Bonelli, G. Angelelli, R. Asnaghi, B. Barbaro, C. Bartolozzi, D. Bielen, et al. Diagnostic Accuracy of Computed Tomographic Colonography for the Detection of Advanced Neoplasia in Individuals at Increased Risk of Colorectal Cancer JAMA, June 17, 2009; 301(23): 2453 - 2461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. West, E. D.J. Courtney, A. P. Poullis, and R. J. Leicester Apoptosis in the Colonic Crypt, Colorectal Adenomata, and Manipulation by Chemoprevention Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bellmunt Future developments in renal cell carcinoma Ann. Onc., May 1, 2009; 20(suppl_1): i13 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kataja, M. Castiglione, and On behalf of the ESMO Guidelines Working Group Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv10 - iv14. [Full Text] [PDF]
|
|
|
|
|
|
C. Jackson, D. Cunningham, J. Oliveira, and On behalf of the ESMO Guidelines Working Group Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv34 - iv36. [Full Text] [PDF]
|
|
|
|
|
|
S. Cascinu, S. Jelic, and On behalf of the ESMO Guidelines Working Group Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv37 - iv40. [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem, J. Oliveira, and On behalf of the ESMO Guidelines Working Group Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv49 - iv50. [Full Text] [PDF]
|
|
|
|
 |
|
 G Attard, C Jameson, J Moreira, P Flohr, C Parker, D Dearnaley, C S Cooper, and J S de Bono Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity J. Clin. Pathol., April 1, 2009; 62(4): 373 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmadi, M. Mohagheghi, M. Karimi, Seyed Ali Golestanha, and M. Naseri Anticancer Effects of HESA-A in Patients With Metastatic Colon Cancer Integr Cancer Ther, March 1, 2009; 8(1): 71 - 74. [Abstract] [PDF]
|
|
|
|
|
|
G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up Anticancer Res, February 1, 2009; 29(2): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Regge, C. Hassan, P. J. Pickhardt, A. Laghi, A. Zullo, D. H. Kim, F. Iafrate, and S. Morini Impact of Computer-aided Detection on the Cost-effectiveness of CT Colonography Radiology, February 1, 2009; 250(2): 488 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga, H. Mellsted, and D. Kerr ESMO's new strategic plan: our society's road to the future of oncology Ann. Onc., January 1, 2009; 20(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, and J. P. A. Ioannidis Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer J Natl Cancer Inst, December 17, 2008; 100(24): 1780 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Naidu and P. B. Rajesh Developments in the Management of Patients with Lung Cancer in the United Kingdom Have Improved Quality of Care Proceedings of the ATS, December 1, 2008; 5(8): 816 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Austoker and P. Hewitson Screening for colorectal cancer BMJ, November 20, 2008; 337(nov20_2): a2207 - a2207. [Full Text]
|
|
|
|
 |
|
 A C Ford, S J O Veldhuyzen van Zanten, C C Rodgers, N J Talley, N B Vakil, and P Moayyedi Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis Gut, November 1, 2008; 57(11): 1545 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Clark, A. Coulson, C. Dalgliesh, P. Rajan, S. M. Nicol, S. Fleming, R. Heer, L. Gaughan, H. Y. Leung, D. J. Elliott, et al. The RNA Helicase p68 Is a Novel Androgen Receptor Coactivator Involved in Splicing and Is Overexpressed in Prostate Cancer Cancer Res., October 1, 2008; 68(19): 7938 - 7946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C von Plessen, T-E Strand, T Wentzel-Larsen, E Omenaas, N Wilking, S Sundstrom, and S Sorenson Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study Thorax, October 1, 2008; 63(10): 866 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A F van Rijn, L G M van Rossum, M Deutekom, R J F Laheij, P M M Bossuyt, P Fockens, E Dekker, and J B M J Jansen Getting adequate information across to colorectal cancer screening subjects can be difficult J Med Screen, September 1, 2008; 15(3): 149 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Casado, P. Pfeiffer, J. Feliu, M. Gonzalez-Baron, L. Vestermark, and H. A. Jensen UFT (tegafur-uracil) in rectal cancer Ann. Onc., August 1, 2008; 19(8): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma Ann. Onc., August 1, 2008; 19(8): 1470 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
On behalf of ESMO and J. Baselga Creating a stronger front against cancer: ESMO and ECCO join forces Ann. Onc., August 1, 2008; 19(8): 1367 - 1368. [Full Text] [PDF]
|
|
|
|
|
|
G. Giaccone and P. A. Zucali Src as a potential therapeutic target in non-small-cell lung cancer Ann. Onc., July 1, 2008; 19(7): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pozzo and C. Barone Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents? Oncologist, July 1, 2008; 13(7): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 Ann. Onc., May 1, 2008; 19(5): 853 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann. Onc., May 1, 2008; 19(5): 920 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Perry, M. Broeders, C. de Wolf, S. Tornberg, R. Holland, and L. von Karsa European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document Ann. Onc., April 1, 2008; 19(4): 614 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bosetti, P. Bertuccio, F. Levi, F. Lucchini, E. Negri, and C. La Vecchia Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis Ann. Onc., April 1, 2008; 19(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boyle Favorable trends in cancer mortality in the European Union but no room for complacency Ann. Onc., April 1, 2008; 19(4): 605 - 606. [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Smits, L. J. Schouten, B. A.C. van Dijk, C. A. Hulsbergen-van de Kaa, K. A.D. Wouters, E. Oosterwijk, M. van Engeland, and P. A. van den Brandt Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis Clin. Cancer Res., February 1, 2008; 14(3): 782 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr Editor-in- New wave Ann. Onc., January 1, 2008; 19(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Amos Successful design and conduct of genome-wide association studies Hum. Mol. Genet., October 15, 2007; 16(R2): R220 - R225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, H. Zhou, J. R.K. Modzelewski, R. Kalak, J. M. Blair, M. J. Seibel, and C. R. Dunstan Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone Cancer Res., October 1, 2007; 67(19): 9542 - 9548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ellershaw Care of the dying: what a difference an LCP makes! Palliative Medicine, July 1, 2007; 21(5): 365 - 368. [PDF]
|
|
E-letters:
Read all E-letters
- Estimates of Female Malignant Breast Cancer Incidence in Great Britain and Ireland in 2006
- Patrick S Carroll, et al.
- Annals of Oncology, 13 Mar 2007 [Full text]
- Estimates of cancer incidence in Germany
- Alexander Katalinic, et al.
- Annals of Oncology, 7 Jun 2007 [Full text]